A Loughborough University student has developed a new medical device that could transform how prostate health is assessed and monitored.
For over a century, surgeons performing delicate procedures have relied on stereoscopic microscopes to gain a sense of depth. These tools mimic human vision by presenting slightly different images to each eye, allowing the brain to perceive three-dimensional structures—a crucial aid when working with fragile blood vessels or intricate brain tissue. Despite modern upgrades like digital displays and video capture, today’s operating microscopes still depend on the same core principle: two views, interpreted by the human brain.
In modern hospitals, timely and accurate decision-making is essential—especially in radiology, where contrast media consultations often require rapid answers rooted in complex clinical guidelines. Yet, physicians are frequently forced to make these decisions under pressure, without immediate access to all relevant information. This challenge is particularly critical for institutions that must also safeguard patient data by avoiding cloud-based tools.
In recent years, the analysis of single-cell and spatial data has revolutionized biomedical research, making it possible to observe what happens in biological samples with an unprecedented level of detail. Interpreting this data, however, is not easy because different software offers different results which are hard to compare.
A combination of high-resolution imaging and machine learning, also known as artificial intelligence (AI), can track cells damaged from injury, aging, or disease, and that no longer grow and reproduce normally, a new study shows.
AI-powered system integrates real-time PCR data for nationwide pathogen tracking, enabling faster public health responses and smarter diagnostic strategies.
Boston Scientific (NYSE: BSX)+
announced today that the FDA approved an expansion to the label of its Farapulse pulsed field ablation (PFA) system.
Chronic wounds are a major medical challenge, burdening health care systems with billions of dollars in costs every year. Pioneer Fellow Börte Emiroglu is developing a new product: a selective, sponge-like hydrogel that reduces inflammatory signals and actively promotes healing.
FDA clears assay as companion diagnostic for ZEGFROVY™ and broad tumor profiling, advancing precision oncology diagnostics.
Ceramic-based hip resurfacing implant gains European regulatory approval, offering patients a bone-preserving, metal-free alternative for hip joint restoration.